查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974083

單株抗體市場分析及至2035年的預測：依類型、產品、應用、技術、最終用戶、製程、服務、劑型、部署方式及模式分類

Monoclonal Antibody Market Analysis and Forecast to 2035: Type, Product, Application, Technology, End User, Process, Services, Form, Deployment, Mode
出版日期: | 出版商: Global Insight Services | 英文 376 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

單株抗體市場預計將從2024年的2,511億美元成長到2034年的8,374億美元，年複合成長率約為12.8%。單株抗體市場涵蓋了針對特定抗原的抗體的開發和商業化。這些生物製藥在治療多種疾病（包括癌症、自體免疫疾病和感染疾病）方面非常重要。生物技術的進步、慢性病盛行率的上升以及對標靶治療日益成長的需求是推動該市場成長的主要因素。生產技術的創新和監管核准的進展進一步加速了市場成長，並為相關人員提供了豐厚的機會。

受生物技術進步和治療應用範圍不斷擴大的推動，單株抗體市場正經歷強勁成長。腫瘤領域成長最為顯著，這主要得益於癌症患者數量的增加以及單株抗體靶向特定癌細胞的有效性。自體免疫疾病領域緊隨其後，受益於能夠有效調節免疫反應的新型抗體的研發。在治療應用方面，感染疾病領域正逐漸成為一個充滿前景的細分市場，單株抗體在病毒感染疾病治療中的應用探索之中。心血管疾病領域也展現出巨大潛力，在研究心臟病相關特定路徑方面取得了進展。對個人化醫療的需求，使得利用單株抗體進行個人化治療成為可能，進一步鞏固了市場的成長動能。對研發的投入和策略合作對於拓展單株抗體在不同疾病領域的治療應用範圍以及推動創新非常重要。

市場區隔
類型 鼠源性、嵌合體、人源化、人源性、雙特異性、偶聯物、多克隆抗體、單克隆
產品 治療性抗體、診斷性抗體、研究性抗體、客製化抗體
用途 腫瘤學、自體免疫疾病、感染疾病、神經病學、心血管疾病、發炎性疾病、移植、血液學
技術 融合瘤技術、噬菌體展示、基因轉殖小鼠、細菌展示、酵母展示、單B細胞擴增
最終用戶 醫院、研究機構、生物製藥公司、診斷檢查室、受託研究機構
流程 體內、體外、In Silico
服務 抗體生產、抗體工程、抗體標記、抗體純化、抗體片段化
形式 液態，凍乾
部署 內部、外包
模式 用於治療和預防

市場概況：

單株抗體市場呈現市場佔有率動態分佈的特點，主要企業持續透過策略性定價和創新產品推出來爭奪主導。在技術進步和各治療領域需求成長的推動下，一系列新型單株抗體產品構成了競爭格局的顯著特徵。定價策略仍然是非常重要的因素，它受到生產複雜性和法規結構的影響，進而影響市場進入和接受度。生物相似藥的採用率激增，反映出市場對更具成本效益的替代方案的需求以及市場滲透率不斷提高的趨勢。單株抗體市場的競爭異常激烈，主要企業透過研發投入和策略聯盟相互競爭。監管的影響在北美和歐洲尤為顯著，嚴格的核准流程決定市場的准入和擴張。專利到期也會影響市場，加速向生物相似藥的轉變，並促進價格競爭。市場動態分析表明，個人化醫療蓬勃發展，而單株抗體正處於這項變革的前沿。受生物技術進步和慢性病日益增多的推動，這個充滿前景的市場環境為相關人員提供了盈利的成長機會。

主要趨勢和促進因素：

受生物技術和基因工程進步的推動，單株抗體市場正經歷強勁成長。癌症和自體免疫疾病等慢性病的日益普遍是主要促進因素，這增加了對標靶治療的需求。單株抗體提供精準的治療選擇，在改善患者預後的同時，最大限度地減少副作用。此外，製藥公司不斷增加的研發投入也促進了市場發展。抗體藥物複合體（ADC）和雙特異性抗體等創新技術提高治療效果，並創造盈利的市場機會。新型單株抗體的加速核准進一步擴大了市場。此外，新冠肺炎疫情凸顯了單株抗體在感染疾病治療中的重要性，加速了其在新治療領域的應用。個人化醫療的趨勢也在塑造著市場，因為單株抗體可以根據每位患者的個別需求進行客製化。憑藉強大的產品平臺和策略合作夥伴關係，單株抗體市場有望持續成長。

壓制與挑戰：

單株抗體市場目前面臨許多重大限制與挑戰。其中一個主要障礙是高昂的生產和研發成本。這種經濟負擔限制了此類治療方法的可近性和可負擔性，尤其是在新興市場。監管的複雜性進一步加劇了這一局面，嚴格的指導方針和漫長的核准流程延緩了新產品的上市時間。供應鏈中斷也是一項重大挑戰。對專業設施和材料的高度依賴使該市場極易受到地緣政治緊張局勢和流行病的影響，可能導致供不應求和成本上升。此外，生物相似藥的興起加劇了競爭壓力，迫使企業在控制成本的同時不斷創新。最後，針對複雜疾病的抗體研發也面臨科學挑戰。儘管技術不斷進步，但針對特定疾病的抗體研發仍十分困難，需要持續的研發投入和大量資金。這些因素共同阻礙了市場的擴張潛力。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 小鼠來源
    • 嵌合體體
    • 人源化
    • 人類
    • 雙特異性抗體
    • 偶聯物
    • 多克隆抗體
    • 單株抗體
  • 市場規模及預測：依產品分類
    • 治療性抗體
    • 診斷抗體
    • 研究抗體
    • 客製化抗體
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 自體免疫疾病
    • 感染疾病
    • 神經病學
    • 心血管疾病
    • 發炎性疾病
    • 移植
    • 血液學
  • 市場規模及預測：依技術分類
    • 融合瘤技術
    • 噬菌體展示
    • 基因改造小鼠
    • 細菌展示
    • 酵母展示
    • 單B細胞擴增
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 研究機構
    • 生物製藥公司
    • 診斷檢查室
    • 受託研究機構
  • 市場規模及預測：依製程分類
    • In vivo
    • 體外
    • In Silico
  • 市場規模及預測：依服務分類
    • 抗體產生
    • 抗體工程
    • 抗體標記
    • 抗體純化
    • 抗體片段化
  • 市場規模及預測：依類型
    • 液體
    • 冷凍乾燥
  • 市場規模及預測：依市場細分
    • 內部開發
    • 外包
  • 市場規模及預測：依模式
    • 治療
    • 預防醫學

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • BioXcel Therapeutics
  • Aptevo Therapeutics
  • Argenx
  • MacroGenics
  • ImmunoGen
  • Xencor
  • Cellectis
  • MorphoSys
  • Alligator Bioscience
  • Genmab
  • AbCellera
  • Kymab
  • Tiziana Life Sciences
  • Harpoon Therapeutics
  • Crescendo Biologics

第9章 關於我們

簡介目錄
Product Code: GIS34412

Monoclonal Antibody Market is anticipated to expand from $251.1 billion in 2024 to $837.4 billion by 2034, growing at a CAGR of approximately 12.8%. The Monoclonal Antibody Market encompasses the development and commercialization of antibodies engineered to target specific antigens. These biologics are pivotal in treating various diseases, including cancers, autoimmune disorders, and infectious diseases. The market is driven by advancements in biotechnology, increasing prevalence of chronic diseases, and the growing demand for targeted therapies. Innovations in production techniques and regulatory approvals further accelerate market growth, offering lucrative opportunities for stakeholders.

The Monoclonal Antibody Market is experiencing robust expansion, propelled by advancements in biotechnology and increasing therapeutic applications. The oncology segment is the top-performing sub-segment, driven by the rising prevalence of cancer and the efficacy of monoclonal antibodies in targeting specific cancer cells. The autoimmune diseases sub-segment follows closely, benefiting from the development of novel antibodies that modulate immune responses effectively. Within the therapeutic application segment, the infectious diseases sub-segment is emerging as a promising area, with monoclonal antibodies being explored for treating viral infections. The cardiovascular diseases sub-segment also shows potential, as research progresses in targeting specific pathways involved in heart diseases. The demand for personalized medicine is further enhancing the market's growth trajectory, as monoclonal antibodies allow for tailored treatment approaches. Investments in research and development, along with strategic collaborations, are pivotal in driving innovation and expanding the therapeutic scope of monoclonal antibodies across diverse medical conditions.

Market Segmentation
TypeMurine, Chimeric, Humanized, Human, Bispecific, Conjugated, Polyclonal, Monoclonal
ProductTherapeutic Antibodies, Diagnostic Antibodies, Research Antibodies, Custom Antibodies
ApplicationOncology, Autoimmune Diseases, Infectious Diseases, Neurology, Cardiovascular Diseases, Inflammatory Diseases, Transplantation, Hematology
TechnologyHybridoma Technology, Phage Display, Transgenic Mice, Bacterial Display, Yeast Display, Single B Cell Amplification
End UserHospitals, Research Institutes, Biopharmaceutical Companies, Diagnostic Laboratories, Contract Research Organizations
ProcessIn Vivo, In Vitro, In Silico
ServicesAntibody Production, Antibody Engineering, Antibody Labeling, Antibody Purification, Antibody Fragmentation
FormLiquid, Lyophilized
DeploymentIn-house, Outsourced
ModeTherapeutic, Prophylactic

Market Snapshot:

The Monoclonal Antibody Market is characterized by a dynamic distribution of market share, with key players continually vying for dominance through strategic pricing and innovative product launches. The competitive landscape is marked by a robust pipeline of new monoclonal antibody products, driven by technological advancements and growing demand across therapeutic areas. Pricing strategies remain a critical aspect, influenced by manufacturing complexities and regulatory frameworks, which in turn shape market accessibility and adoption rates. The industry is witnessing a surge in biosimilar introductions, reflecting a trend towards cost-effective alternatives and broader market penetration. Competition in the Monoclonal Antibody Market is fierce, with leading companies benchmarking against each other through R&D investments and strategic alliances. Regulatory influences play a pivotal role, particularly in North America and Europe, where stringent approval processes dictate market entry and expansion. The market is further influenced by patent expirations, prompting a shift towards biosimilars and fostering competitive pricing. Analyzing market dynamics reveals a trajectory towards personalized medicine, with monoclonal antibodies at the forefront of this evolution. The landscape is poised for growth, driven by advancements in biotechnology and increasing prevalence of chronic diseases, offering lucrative opportunities for stakeholders.

Geographical Overview:

The monoclonal antibody market is experiencing notable growth across various regions, each offering unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in biotechnology research. The region benefits from a strong presence of pharmaceutical giants and a robust pipeline of monoclonal antibody therapies. Europe follows closely, with significant investments in biopharmaceutical R&D and favorable regulatory frameworks. The region's focus on innovative healthcare solutions and personalized medicine enhances its market potential. In Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditures and increasing prevalence of chronic diseases. Emerging economies like China and India are becoming key players due to their large patient populations and improving healthcare systems. Latin America and the Middle East & Africa are emerging markets with growing potential. Latin America's increasing investment in healthcare infrastructure and biotechnology research is driving market growth. Meanwhile, the Middle East & Africa are recognizing the importance of monoclonal antibodies in addressing unmet medical needs, fostering a conducive environment for market expansion.

Key Trends and Drivers:

The monoclonal antibody market is experiencing robust growth, propelled by advancements in biotechnology and genetic engineering. The rising prevalence of chronic diseases, such as cancer and autoimmune disorders, is a significant driver, increasing the demand for targeted therapies. Monoclonal antibodies offer precision treatment options, minimizing adverse effects and improving patient outcomes. The market is further fueled by increased investments in research and development by pharmaceutical companies. Innovations in antibody-drug conjugates and bispecific antibodies are enhancing therapeutic efficacy, creating lucrative opportunities. Regulatory approvals for novel monoclonal antibodies are accelerating, boosting market expansion. Moreover, the COVID-19 pandemic has underscored the importance of monoclonal antibodies in infectious disease management, driving their adoption in new therapeutic areas. The trend towards personalized medicine is also shaping the market, as monoclonal antibodies can be tailored to individual patient needs. With a strong pipeline of products and strategic collaborations, the monoclonal antibody market is poised for sustained growth.

Restraints and Challenges:

The monoclonal antibody market is currently navigating several significant restraints and challenges. One of the primary hurdles is the high cost of production and development. This financial burden limits the accessibility and affordability of these therapies, particularly in emerging markets. Regulatory complexities further exacerbate the situation, with stringent guidelines and lengthy approval processes slowing down the time-to-market for new products. Supply chain disruptions also pose a significant challenge. The reliance on specialized facilities and materials makes the market vulnerable to geopolitical tensions and pandemics, which can lead to shortages and increased costs. Additionally, the rise of biosimilars introduces competitive pressures, compelling companies to innovate continually while managing costs. Lastly, the market faces scientific challenges in targeting complex diseases. Despite technological advances, developing antibodies for certain conditions remains elusive, requiring ongoing research and substantial investment. These factors collectively hinder the market's expansive potential.

Key Players:

BioXcel Therapeutics, Aptevo Therapeutics, Argenx, MacroGenics, ImmunoGen, Xencor, Cellectis, MorphoSys, Alligator Bioscience, Genmab, AbCellera, Kymab, Tiziana Life Sciences, Harpoon Therapeutics, Crescendo Biologics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Form
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Murine
    • 4.1.2 Chimeric
    • 4.1.3 Humanized
    • 4.1.4 Human
    • 4.1.5 Bispecific
    • 4.1.6 Conjugated
    • 4.1.7 Polyclonal
    • 4.1.8 Monoclonal
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Antibodies
    • 4.2.2 Diagnostic Antibodies
    • 4.2.3 Research Antibodies
    • 4.2.4 Custom Antibodies
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Oncology
    • 4.3.2 Autoimmune Diseases
    • 4.3.3 Infectious Diseases
    • 4.3.4 Neurology
    • 4.3.5 Cardiovascular Diseases
    • 4.3.6 Inflammatory Diseases
    • 4.3.7 Transplantation
    • 4.3.8 Hematology
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Hybridoma Technology
    • 4.4.2 Phage Display
    • 4.4.3 Transgenic Mice
    • 4.4.4 Bacterial Display
    • 4.4.5 Yeast Display
    • 4.4.6 Single B Cell Amplification
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Research Institutes
    • 4.5.3 Biopharmaceutical Companies
    • 4.5.4 Diagnostic Laboratories
    • 4.5.5 Contract Research Organizations
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In Vivo
    • 4.6.2 In Vitro
    • 4.6.3 In Silico
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Antibody Production
    • 4.7.2 Antibody Engineering
    • 4.7.3 Antibody Labeling
    • 4.7.4 Antibody Purification
    • 4.7.5 Antibody Fragmentation
  • 4.8 Market Size & Forecast by Form (2020-2035)
    • 4.8.1 Liquid
    • 4.8.2 Lyophilized
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 In-house
    • 4.9.2 Outsourced
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Therapeutic
    • 4.10.2 Prophylactic

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 Technology
      • 5.2.1.5 End User
      • 5.2.1.6 Process
      • 5.2.1.7 Services
      • 5.2.1.8 Form
      • 5.2.1.9 Deployment
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 Technology
      • 5.2.2.5 End User
      • 5.2.2.6 Process
      • 5.2.2.7 Services
      • 5.2.2.8 Form
      • 5.2.2.9 Deployment
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 Technology
      • 5.2.3.5 End User
      • 5.2.3.6 Process
      • 5.2.3.7 Services
      • 5.2.3.8 Form
      • 5.2.3.9 Deployment
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 Technology
      • 5.3.1.5 End User
      • 5.3.1.6 Process
      • 5.3.1.7 Services
      • 5.3.1.8 Form
      • 5.3.1.9 Deployment
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 Technology
      • 5.3.2.5 End User
      • 5.3.2.6 Process
      • 5.3.2.7 Services
      • 5.3.2.8 Form
      • 5.3.2.9 Deployment
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 Technology
      • 5.3.3.5 End User
      • 5.3.3.6 Process
      • 5.3.3.7 Services
      • 5.3.3.8 Form
      • 5.3.3.9 Deployment
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 Technology
      • 5.4.1.5 End User
      • 5.4.1.6 Process
      • 5.4.1.7 Services
      • 5.4.1.8 Form
      • 5.4.1.9 Deployment
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 Technology
      • 5.4.2.5 End User
      • 5.4.2.6 Process
      • 5.4.2.7 Services
      • 5.4.2.8 Form
      • 5.4.2.9 Deployment
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 Technology
      • 5.4.3.5 End User
      • 5.4.3.6 Process
      • 5.4.3.7 Services
      • 5.4.3.8 Form
      • 5.4.3.9 Deployment
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 Technology
      • 5.4.4.5 End User
      • 5.4.4.6 Process
      • 5.4.4.7 Services
      • 5.4.4.8 Form
      • 5.4.4.9 Deployment
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 Technology
      • 5.4.5.5 End User
      • 5.4.5.6 Process
      • 5.4.5.7 Services
      • 5.4.5.8 Form
      • 5.4.5.9 Deployment
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 Technology
      • 5.4.6.5 End User
      • 5.4.6.6 Process
      • 5.4.6.7 Services
      • 5.4.6.8 Form
      • 5.4.6.9 Deployment
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 Technology
      • 5.4.7.5 End User
      • 5.4.7.6 Process
      • 5.4.7.7 Services
      • 5.4.7.8 Form
      • 5.4.7.9 Deployment
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 Technology
      • 5.5.1.5 End User
      • 5.5.1.6 Process
      • 5.5.1.7 Services
      • 5.5.1.8 Form
      • 5.5.1.9 Deployment
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 Technology
      • 5.5.2.5 End User
      • 5.5.2.6 Process
      • 5.5.2.7 Services
      • 5.5.2.8 Form
      • 5.5.2.9 Deployment
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 Technology
      • 5.5.3.5 End User
      • 5.5.3.6 Process
      • 5.5.3.7 Services
      • 5.5.3.8 Form
      • 5.5.3.9 Deployment
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 Technology
      • 5.5.4.5 End User
      • 5.5.4.6 Process
      • 5.5.4.7 Services
      • 5.5.4.8 Form
      • 5.5.4.9 Deployment
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 Technology
      • 5.5.5.5 End User
      • 5.5.5.6 Process
      • 5.5.5.7 Services
      • 5.5.5.8 Form
      • 5.5.5.9 Deployment
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 Technology
      • 5.5.6.5 End User
      • 5.5.6.6 Process
      • 5.5.6.7 Services
      • 5.5.6.8 Form
      • 5.5.6.9 Deployment
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 Technology
      • 5.6.1.5 End User
      • 5.6.1.6 Process
      • 5.6.1.7 Services
      • 5.6.1.8 Form
      • 5.6.1.9 Deployment
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 Technology
      • 5.6.2.5 End User
      • 5.6.2.6 Process
      • 5.6.2.7 Services
      • 5.6.2.8 Form
      • 5.6.2.9 Deployment
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 Technology
      • 5.6.3.5 End User
      • 5.6.3.6 Process
      • 5.6.3.7 Services
      • 5.6.3.8 Form
      • 5.6.3.9 Deployment
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 Technology
      • 5.6.4.5 End User
      • 5.6.4.6 Process
      • 5.6.4.7 Services
      • 5.6.4.8 Form
      • 5.6.4.9 Deployment
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 Technology
      • 5.6.5.5 End User
      • 5.6.5.6 Process
      • 5.6.5.7 Services
      • 5.6.5.8 Form
      • 5.6.5.9 Deployment
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 BioXcel Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Aptevo Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Argenx
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 MacroGenics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 ImmunoGen
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Xencor
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cellectis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 MorphoSys
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Alligator Bioscience
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Genmab
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 AbCellera
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Kymab
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Tiziana Life Sciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Harpoon Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Crescendo Biologics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us